Comparison of recombinant tissue plasminogen activator therapy in short-term and mid-term prognosis of acute ischemic stroke patients and control group

Abstract

This study aimed to compare short- and mid-term prognosis of therapy with r-TPA in a controlled setting. Methods & Materials A total of 134 patients with computed tomographic documented acute ischemic stroke who were admitted within 3 h after the onset of symptoms received intravenous r-TPA. Another group of patients (n=57) who received aspirin served as controls. The MRS and NIHSS were documented at baseline, and on week 1 month 3 posttreatment as outcome variables. The incidence of intracranial hemorrhage and the mortality rate were also documented. Results Patients in the r-TPA group were 85 males (63.4%) and 49 females (36.6%) with the mean age of 65.43±12.66 years (33-88). There were 37 males (64.9%) and 20 females (35.1%) in the control group with the mean age of 68.00±11.66 years (33-88) (p=0.85 and 0.19, respectively). The mean MRSs at baseline, on week 1 and on month 3 were 3.73±1.56, 3.09±1.90 and 3.14±0.20 in the case group, and 3.53±1.75, 3.51±1.53 and 3.47±0.26 in the control group (p<0.001). The mean NIHSSs at baseline, on week 1 and on month 3 were 13.61±6.20, 13.00±1.04 and 19.05±1.87 in the case group, and 13.81±6.99, 16.13±1.30 and 17.98±2.10 in the control group (p<0.001). The incidence of intracranial hemorrhage was 14.2% in the case group and 8.8% in the control group (p=0.30). The mortality rates were 29.1% and 19.3%, respectively (p=0.16).